5 times New Highs Were Reached By Aurinia Pharmaceuticals Inc. (AUPH) In The Last Five Days

The stock of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) increased by increased by $5.91 on Friday to finish at $28.00, up 26.75 percent. The last five days have seen an average of 4,216,600 shares of common stock traded. 11 times new highs were reached in the current year, with a gain of $14.17. The average number of shares traded over the last 20 days was 3,417,000, while the average volume over the last 50 days totaled 3,874,874.

AUPH stock appreciated 19.10% since last month. On 10/06/21, the company’s shares reached a one-month low of $17.65. The stock touched a high of $24.18 on 10/22/21, after rallying from a low of $9.72 in 52 weeks. The price of AUPH stock has risen by 102.46% or $14.17 this year, reaching a new high 11 times. Still, the stock price is up 15.80% from the 52-week high.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


Insider Transactions

There have been 34 days since Aurinia Pharmaceuticals Inc. (AUPH) last reported insider trading activity on Sep 21. On Sep 21, EVP of Research Huizinga Robert Bindert sold 32,500 shares at $23.99 each. This transaction resulted in the insider making $779,533. On Sep 21, Martin Michael Robert sold 87,500 shares at a price of US$24.02. After the transaction, the insider now owns 176,861 shares. Chief Business Officer Martin Michael Robert had earlier sold 28,500 shares on Sep 20 for $21.65 a share. The transaction was completed for $616,975.

Valuation Metrics

Beta for the stock is 0.32. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 49.15, the price-to-book (PB) ratio of 10.81.

For the three months ended September 29, Aurinia Pharmaceuticals Inc.’s quick ratio was 11.30, while its current ratio was 11.90, indicating its ability to pay off its debt. As far as profitability goes, gross margin for the trailing twelve months is 99.40% percent. Based on annual data, it had gross profit of $147.6 million and revenue of $50.12 million.

Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. There was a -25.60% return on investment (ROI) in the past year. ROE has averaged -68.79 in the past year for the broader industry.

Earnings Surprise

According to Aurinia Pharmaceuticals Inc.’s quarterly financial report for the quarter that ended September 29. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $6.62 million, while revenues rose by 100.0% to $0.91 million. It was predicted that Aurinia Pharmaceuticals Inc.’s quarterly earnings would be -$0.16, but it ended up being -$0.15, beating the consensus by -6.70%. EBITDA was -$47.4 million for the quarter. At the end of Aurinia Pharmaceuticals Inc.’s most recent quarter ended September 29, its liabilities totaled 54.01 million, while its total debt was $8.88 million. Equity owned by shareholders amounts to $128.4 million.

Technical Picture

Here’s a quick look at Aurinia Pharmaceuticals Inc.’s (AUPH) price momentum from a technical perspective. As of 22 October, the RSI 9-day stood at 80.55%, suggesting the stock is Overbought, with a 120.30% historical volatility rate.

The stochastic %K and %D were 83.07% and 63.78% respectively, while the average true range (ATR) was 1.92. Based on the 14-day stochastic reading of 100.00%, the RSI (14) reading is 74.40%. On the 9-day MACD Oscillator, the stock is at 2.03, and the 14-day reading is at 2.60.

Analyst Ratings

In a note to investors, H.C. Wainwright maintained its a Buy rating on Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH). However, the firm raised their price target to $35, indicating a possible increase of 6.67% in the stock price. Analysts have assigned Aurinia Pharmaceuticals Inc. (AUPH) an Buy rating. AUPH is a stock that is recommended for selling by 0 brokerage firms, while 1 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 7 others recommend it as a buy.

What is AUPH’s price target for the next 12 months?

The current consensus forecast for the stock is between $23.00 and $35.00, with a median target price of $31.00. In analyzing these forecasts, the average price target given by analysts for Aurinia Pharmaceuticals Inc. (AUPH) is $30.00.


Please enter your comment!
Please enter your name here


Hot Topics

Related Videos

Related Videos

Related Articles



Download Free eBook For



100% free. stop anytime no spam